Result of AGM and voting results
Summary by AI BETAClose X
30 June 2026
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or "the Company")
Result of AGM and voting results
Ondine Biomedical (AIM: OBI) announces that all resolutions set out in the Notice of AGM dated 4 June 2026 were duly passed at its Annual General Meeting ("AGM") held on 30 June 2026.
The voting results of the AGM were as follows:
|
|
In Favor |
Against |
Withheld |
|||
Resolution |
Votes |
% |
Votes |
% |
Votes |
% |
1. Election of Directors |
|
|
|
|
|
|
Carolyn Cross |
314,158,038 |
100.00 |
0 |
0.00 |
0 |
0.00 |
Nicolas G. Loebel |
314,158,038 |
100.00 |
0 |
0.00 |
0 |
0.00 |
Jean Charest |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
Jean Duvall |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
Junaid Bajwa |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
Margaret Shaw |
261,714,535 |
83.31 |
0 |
0.00 |
52,443,503 |
16.69 |
2. Appointment of Auditors |
311,758,038 |
99.24 |
0 |
0.00 |
2,400,000 |
0.76 |
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
|
|
|
Strand Hanson Limited (Nominated & Joint Financial Adviser) |
|
|
James Harris, Richard Johnson, Imogen Ellis |
+44 (0)20 7409 3494 |
|
|
|
|
Peel Hunt LLP (Broker & Joint Financial Adviser) |
|
|
James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
|
|
|
|
5654 & Company (Financial PR and IR Adviser) |
ondinebiomedical@5654.co.uk |
|
Matthew Neal, Chris Gardner, Melissa Gardiner |
+44 0791 7800 011 +44 0775 7697 357 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms.
Ondine's lead product, Steriwave®, is authorized for nasal decolonisation in Canada and certain international markets. In the United States, the technology has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration and recently completed enrolment in its Phase 3 clinical trial.
The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund